Research Articles

Research articles concerning NAFLD are extracted from PubMed. For each individual article, related therapeutic strategies, targets, drugs and associated diseases in NAFLDkb are presented with knowledge graphs.

stats1
stats2
stats3
stats4

Search for:

     Telmisartan
32 records.
Article ID PMID Source Title Publish Year
A04567 33578449 Biotechnol Appl Biochem An insight into the role of telmisartan as PPAR-γ/α dual activator in the management of nonalcoholic fatty liver disease. 2021 Details
A06304 32934967 J Biol Methods An in vitro model of hepatic steatosis using lipid loaded induced pluripotent stem cell derived hepatocyte like cells. 2020 Details
A06679 32782954 JGH Open Effect of telmisartan and vitamin E on liver histopathology with non-alcoholic steatohepatitis: A randomized, open-label, noninferiority trial. 2020 Details
A11195 31004566 Biochem Pharmacol Telmisartan and/or chlorogenic acid attenuates fructose-induced non-alcoholic fatty liver disease in rats: Implications of cross-talk between angiotensin, the sphingosine kinase/sphingoine-1-phosphate pathway, and TLR4 receptors. 2019 Details
A11542 30850637 Sci Rep Connectivity mapping of angiotensin-PPAR interactions involved in the amelioration of non-alcoholic steatohepatitis by Telmisartan. 2019 Details
A12660 30341231 Postgrad Med J Pharmacological interventions for non-alcoholic fatty liver disease: a systematic review and network meta-analysis. 2018 Details
A14009 29636553 Hypertens Res The role of the angiotensin II type I receptor blocker telmisartan in the treatment of non-alcoholic fatty liver disease: a brief review. 2018 Details
A15335 28962213 Exp Ther Med Effects of telmisartan on improving leptin resistance and inhibiting hepatic fibrosis in rats with non-alcoholic fatty liver disease. 2017 Details
A18521 27074921 Dig Dis Sci Treatment with Oxidized Phospholipids Directly Inhibits Nonalcoholic Steatohepatitis and Liver Fibrosis Without Affecting Steatosis. 2016 Details
A18625 27028410 Liver Int Lipid disorder and intrahepatic renin-angiotensin system activation synergistically contribute to non-alcoholic fatty liver disease. 2016 Details
A18986 26831610 Saudi J Gastroenterol Effect of telmisartan on histological activity and fibrosis of non-alcoholic steatohepatitis: A 1-year randomized control trial. 2017 Details
A20136 26133820 Zhonghua Gan Zang Bing Za Zhi [Effects of telmisartan on resistin expression in a rat model of nonalcoholic steatohepatitis and insulin resistance]. 2015 Details
A22700 25796814 Wiad Lek Combined effect of appointment telmisartan and atorvastatin on hemodynamic indicators and the indicators of lipid profile in patients with arterial hypertension combined with obesity and steatohepatitis. 2014 Details
A23089 24048504 Med Mol Morphol Linagliptin alleviates hepatic steatosis and inflammation in a mouse model of non-alcoholic steatohepatitis. 2013 Details
A23157 23997767 Int J Endocrinol Effect of Telmisartan or Losartan for Treatment of Nonalcoholic Fatty Liver Disease: Fatty Liver Protection Trial by Telmisartan or Losartan Study (FANTASY). 2013 Details
A23694 23560443 Int J Exp Pathol Inhibition of Glutaminyl Cyclases alleviates CCL2-mediated inflammation of non-alcoholic fatty liver disease in mice. 2013 Details
A24444 22886508 J Gastroenterol Angiotensin II type 1 receptor antagonist prevents hepatic carcinoma in rats with nonalcoholic steatohepatitis. 2012 Details
A25133 22152320 Zhonghua Gan Zang Bing Za Zhi [Effects of telmisartan on nonalcoholic steatohepatitis rat model by activating peroxisome proliferator-activated receptor r]. 2011 Details
A25920 21327395 Cell Tissue Res Telmisartan improves nonalcoholic steatohepatitis in medaka (Oryzias latipes) by reducing macrophage infiltration and fat accumulation. 2011 Details
A26370 20578268 Hepatology A meta-analysis of randomized trials for the treatment of nonalcoholic fatty liver disease. 2010 Details
A26993 19386026 Liver Int Telmisartan attenuates progression of steatohepatitis in mice: role of hepatic macrophage infiltration and effects on adipose tissue. 2009 Details
A27065 19230890 Atherosclerosis Losartan reduces liver expression of plasminogen activator inhibitor-1 (PAI-1) in a high fat-induced rat nonalcoholic fatty liver disease model. 2009 Details
A27214 18972077 Adv Ther Angiotensin receptor blockers in the treatment of NASH/NAFLD: could they be a first-class option? 2008 Details
A27262 18813860 Int J Mol Med Therapeutic effect of ARBs on insulin resistance and liver injury in patients with NAFLD and chronic hepatitis C: a pilot study. 2008 Details
A35407 20818485 Int J Mol Med Prevention and regression of non-alcoholic steatohepatitis (NASH) in a rat model by metabosartan, telmisartan. 2010 Details
A35999 19248193 World J Gastroenterol Angiotensin-receptor blockers as therapy for mild-to-moderate hypertension-associated non-alcoholic steatohepatitis. 2009 Details
A36511 17963695 Biochem Biophys Res Commun Telmisartan prevents hepatic fibrosis and enzyme-altered lesions in liver cirrhosis rat induced by a choline-deficient L-amino acid-defined diet. 2007 Details
A36710 17410441 Dig Dis Sci Telmisartan, an angiotensin II type 1 receptor blocker, controls progress of nonalcoholic steatohepatitis in rats. 2007 Details
A44091 29785143 J Exp Pharmacol Pilot study of the antifibrotic effects of the multikinase inhibitor pacritinib in a mouse model of liver fibrosis. 2018 Details
A48042 25866507 Gastroenterol Res Pract Treatment of nonalcoholic steatohepatitis in adults: present and future. 2015 Details
A49652 35678800 Turk J Gastroenterol Effects of Orlistat or Telmisartan on the Serum Free Fatty Acids in Non-alcoholic Fatty Liver Disease Patients: An Open-Labeled Randomized Controlled Study. 2022 Details
A49827 35625927 Biomedicines A Nine-Strain Bacterial Consortium Improves Portal Hypertension and Insulin Signaling and Delays NAFLD Progression In Vivo. 2022 Details